Study on ziprasidone combined with clonazepam in the treatment of agitation of schizophrenia

doi:10.3969/j.issn.1674-490X.2013.04.002

Abstract

Abstract: Objective To investigate the efficacy and safety of intramuscular ziprasidone combined with clonazepam in the treatment of agitation of schizophrenia. Methods 80 cases with agitation of schizophrenia patients were randomly divided into 2 groups, were treated with intramuscular ziprasidone combined with clonazepam and haloperidol. The evaluating indicators include the Brief Psychiatric Rating Scale (BPRS) score, behavior rating scale (BARS) and BPRS agitated symptoms subscale scores;Also include Simpson–Angus extrapyramidal side effects Rating Scale. Results From baseline to endpoint the subject BPRS agitation symptoms subscale score reduced more than 30%(>30%) was judged to be effective. The effective subjects of ziprasidone group was 37 cases (92.5%), and 32 cases in haloperidol group (80%).The two groups had no signiifcant difference (χ2=2.635, P=0.193). The extrapyramidal side effects occur in ziprasidone group was 1 cases (2.5%) less than haloperidol group of 14 cases (35%) (χ2=13.767, P<0.001). Conclusion Intramuscular ziprasidone combined with clonazepam in the treatment of agitation of schizophrenia is as efficacy as haloperidol, the extrapyramidal side effects is less than that of haloperidol.

Key words: ziprasidone, clonazepam, schizophrenia, agitation

CLC Number:

R749.3

WANG Jian,DUAN Fei. Study on ziprasidone combined with clonazepam in the treatment of agitation of schizophrenia[J]. Medical Reserch and Education, 2013, 30(4): 5-9.

References

[1] 张疆莉, 张建宏, 申彪. 齐拉西酮注射液与氟哌啶醇注射液治疗急性精神分裂症的疗效及安全性比较 [J]. 中国现代药物应用 2010.doi:10.3969/j.issn.1673-9523.2010.12.108
[2] 陈琦, 薄奇静, 迟勇, 赵幸福, 李晓驷, 谭云龙, 杜波, 王传跃, CHEN Qi, BO Qi-jing, CHI Yong, ZHAO Xing-fu, LI Xiao-si, TAN Yun-long, DU Bo, WANG Chuan-yue. 齐拉西酮合并氯硝西泮治疗急性期伴激越精神分裂症患者的对照研究 [J]. 临床精神医学杂志 2012.
[3] 李四冬, 周严俊, 戢秋明, 江凌翔, Li Sidong, Zhou Yanjun, Ji Qiuming, Jiang Lingxiang. 齐拉西酮注射剂与氟哌啶醇注射剂治疗精神分裂症急性期患者的对照研究 [J]. 上海精神医学 2010.doi:10.3969/j.issn.1002-0829.2010.04.011
[4] 陈光财, 邓方渝, 王德燧, 许可, CHEN Guang-cai, DENG Fang-yu, WANG De-sui, XU Ke. 齐拉西酮注射液治疗精神分裂症急性期的对照研究 [J]. 安徽医药 2010.doi:10.3969/j.issn.1009-6469.2010.09.041
[5] Brook S. [J]. The journal of clinical psychiatry 2003.
[6] Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP. Treatment of behavioral emergencies 2005. [J]. Journal of psychiatric practice 2005, Suppl.1(Suppl.1).
[7] San L, Arranz B, Escobar R. Pharmacological management of acutely agitated schizophrenic patients. [J]. Current pharmaceutical design 2005, 19(19).
[8] Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. [J]. Clinical therapeutics 2002, 1(1).
[9] Zhang, H., Wang, G., Zhao, J., Xie, S., Xu, X., Shi, J., Deng, H., Li, K., Gao, C., Wang, X., Vanderburg, D., Pan, S., Tang, H., Shu, L., Karayal, O.N.. Intramuscular ziprasidone versus haloperidol for managing agitation in chinese patients with schizophrenia [J]. Journal of clinical psychopharmacology 2013, 2(2).
[10] Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. [J]. The journal of clinical psychiatry 2008, Suppl.1(Suppl.1).
[11] 舒良. 精神分裂症防治指南 [M]. 北京:北京大学医学出版社 2007.
[12] JANGRO W C, PREVAL H, SOUTHARD R. Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents:case-control study [J]. Child Adolesc Psychiatry Ment Health 2009, 3(01).